IRIS UniCatt

Chiricozzi, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.352
NA - Nord America 3.162
EU - Europa 2.576
SA - Sud America 1.216
AF - Africa 227
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 3
Totale 11.558
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.994
SG - Singapore 2.349
BR - Brasile 1.012
CN - Cina 806
IT - Italia 509
SE - Svezia 491
DE - Germania 334
IE - Irlanda 315
VN - Vietnam 237
ID - Indonesia 233
FR - Francia 173
GB - Regno Unito 153
RU - Federazione Russa 147
IN - India 146
FI - Finlandia 131
CI - Costa d'Avorio 116
HK - Hong Kong 106
CA - Canada 81
AR - Argentina 76
BD - Bangladesh 71
IQ - Iraq 63
KR - Corea 57
ES - Italia 52
JP - Giappone 50
MX - Messico 49
NL - Olanda 46
PL - Polonia 46
TR - Turchia 39
AT - Austria 35
EC - Ecuador 34
PK - Pakistan 33
ZA - Sudafrica 32
SA - Arabia Saudita 24
MA - Marocco 22
AU - Australia 21
KE - Kenya 20
UA - Ucraina 20
CZ - Repubblica Ceca 19
CO - Colombia 18
RO - Romania 17
CL - Cile 16
VE - Venezuela 16
JO - Giordania 14
AE - Emirati Arabi Uniti 13
PY - Paraguay 13
CH - Svizzera 12
PE - Perù 12
IR - Iran 11
TH - Thailandia 11
TN - Tunisia 11
UZ - Uzbekistan 11
GR - Grecia 10
LT - Lituania 10
BE - Belgio 9
BO - Bolivia 9
IL - Israele 9
EG - Egitto 8
PT - Portogallo 8
CR - Costa Rica 7
HU - Ungheria 7
KZ - Kazakistan 7
NP - Nepal 7
UY - Uruguay 7
BG - Bulgaria 6
JM - Giamaica 6
AL - Albania 5
DO - Repubblica Dominicana 5
ET - Etiopia 5
HN - Honduras 5
KW - Kuwait 5
LB - Libano 5
PA - Panama 5
PH - Filippine 5
RS - Serbia 5
TT - Trinidad e Tobago 5
AZ - Azerbaigian 4
CY - Cipro 4
HR - Croazia 4
TW - Taiwan 4
BH - Bahrain 3
GE - Georgia 3
MY - Malesia 3
PS - Palestinian Territory 3
QA - Qatar 3
SY - Repubblica araba siriana 3
AM - Armenia 2
AO - Angola 2
BB - Barbados 2
DZ - Algeria 2
EE - Estonia 2
EU - Europa 2
GY - Guiana 2
LA - Repubblica Popolare Democratica del Laos 2
ME - Montenegro 2
MM - Myanmar 2
NA - Namibia 2
NG - Nigeria 2
NO - Norvegia 2
OM - Oman 2
SI - Slovenia 2
Totale 11.541
Salva come PNG Salva come JPEG
Città #
Singapore 937
Ashburn 619
Chandler 425
Dublin 310
Beijing 237
Jakarta 214
Hefei 149
New York 135
Milan 123
Abidjan 115
Bremen 113
Moscow 105
Hong Kong 104
Princeton 99
Rome 93
Boston 88
Ho Chi Minh City 88
Los Angeles 86
Frankfurt am Main 83
São Paulo 82
Helsinki 79
Dallas 69
Hanoi 51
Munich 50
Chicago 49
Seoul 49
Kent 46
Wilmington 41
London 35
Nuremberg 33
Tokyo 31
Washington 31
Pune 30
Rio de Janeiro 30
San Mateo 30
Warsaw 30
Montreal 29
Brasília 28
The Dalles 28
Santa Clara 27
Brooklyn 26
Lappeenranta 26
Seattle 25
Turku 25
Belo Horizonte 23
Paris 23
Stockholm 23
Atlanta 22
Amsterdam 21
Curitiba 21
Boardman 20
Hyderabad 20
Mexico City 20
Vienna 20
Johannesburg 19
Baghdad 18
Denver 18
Dhaka 18
Nairobi 18
Toronto 17
Houston 16
Brno 15
Council Bluffs 15
North Bergen 15
Haiphong 14
Hangzhou 14
Lauterbourg 14
Porto Alegre 14
Redwood City 14
Roubaix 14
Amman 13
Chennai 13
Dearborn 13
Guarulhos 13
Manchester 13
Orem 13
San Francisco 13
Ankara 12
Buffalo 12
Düsseldorf 12
Shanghai 12
Guayaquil 11
Phoenix 11
Poplar 11
Santiago 11
Da Nang 10
Fairfield 10
Jeddah 10
Ottawa 10
Recife 10
Salvador 10
Tashkent 10
Barcelona 9
Bexley 9
Brussels 9
Guangzhou 9
Nanjing 9
Naples 9
Portsmouth 9
Quito 9
Totale 5.894
Salva come PNG Salva come JPEG
Nome #
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study 270
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study 156
Clinical and ultrasonographic profile of adalimumab-treated hidradenitis suppurativa patients: A real-life monocentric experience 139
Assessment of alopecia areata universalis successfully treated with upadacitinib 111
Therapeutic impact and management of persistent head and neck atopic dermatitis in dupilumab-treated patients 108
Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis 107
Case report: Dupilumab treatment improved type 2 disorders in a patient with IPEX syndrome diagnosis 104
Alopecia Areata Occurring after COVID-19 Vaccination: A Single-Center, Cross-Sectional Study 98
Periocular molluscum contagiosum in an atopic dermatitis patient treated with upadacitinib 97
Dupilumab improves clinical manifestations, symptoms and quality of life in adult patients with chronic nodular prurigo 97
Similar Levels of Efficacy of Two Different Maintenance Doses of Adalimumab on Clinical Severity and Quality of Life of Patients with Hidradenitis Suppurativa 96
Biological agents targeting interleukin-13 for atopic dermatitis 96
Improvement of severe facial seborrheic dermatitis following low-dose isotretinoin therapy 95
Dupilumab-associated ocular adverse events are predicted by low tear break-up time and correlate with high IL-33 tear concentrations in patients with atopic dermatitis 93
Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments 92
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 91
A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis 90
A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis 89
Baricitinib: therapeutic potential for moderate to severe atopic dermatitis 88
Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis 88
Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience 87
The preclinical discovery and development of deucravacitinib for the treatment of psoriasis 87
Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis 87
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study 87
Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis 86
New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis 86
Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation 84
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis 84
Real-Time Confocal Imaging for Hidradenitis Suppurativa: Description of Morphological Aspects and Focus on the Role of Follicular Ostia 84
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 83
Clinical, epidemiological, and therapeutic hallmarks of pyoderma gangrenosum: a case series of 35 patients 83
Pediatric Hidradenitis Suppurativa: A Cross-Sectional Study on Clinical Features and Treatment Approaches 83
Flares as dynamic predictive factor of response to adalimumab in hidradenitis suppurativa: real-life data 82
Drug survival of biologics and non-biologics in patients affected by palmoplantar psoriasis: a “real-world”, mono-center experience 81
Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy 81
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry 80
Novel Therapeutic Strategies in the Topical Treatment of Atopic Dermatitis 80
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era 80
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 80
COVID-19 hygiene measures: hand eczema and insights into ACE2 and integrins as key molecules for SARS-CoV-2 cutaneous transmission 80
Overview of Atopic Dermatitis in Different Ethnic Groups 78
Long-term management of moderate-to-severe adult atopic dermatitis: A consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Association of Italian Territorial and Hospital Allergists and Immunologists (AAIITO), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA), and the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC) 78
Topical treatment of severe xerosis: Results of an observational study 78
Real-Time Confocal Imaging for Hidradenitis Suppurativa: Description of Morphological Aspects and Focus on the Role of Follicular Ostia 77
Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment 76
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 76
Characterization of comorbid conditions burdening hidradenitis suppurativa: A multicentric observational study 76
Investigational systemic drugs for moderate to severe plaque psoriasis: What's new? 75
Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study 75
TSLP-activated dendritic cells induce human T follicular helper cell differentiation through OX40-ligand 75
Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis: results from an Italian multicenter study 74
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations 74
A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic 74
Successful response of upadacitinib in different clinical phenotypes of atopic dermatitis 74
Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study 73
AISI: A New Disease Severity Assessment Tool for Hidradenitis Suppurativa 72
Creation of a severity index for hidradenitis suppurativa that includes a validated quality-of-life measure: the HIDRAscore 71
European consensus statement on phenotypes of pustular psoriasis 71
Hidradenitis Suppurativa Associated with Down Syndrome Is Characterized by Early Age at Diagnosis 70
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study 69
Histological features of immune cell infiltrate in lesional skin correlate with therapeutic response to dupilumab 68
COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus 68
Low grade of satisfaction related to the use of current systemic therapies among pustular psoriasis patients: a therapeutic unmet need to be fulfilled 67
Successful response to upadacitinib in the treatment of atopic dermatitis lesions involving sensitive and visible areas resistant to dupilumab treatment 66
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year 66
Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study 66
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis 66
Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study 65
Current therapeutic paradigm in pediatric atopic dermatitis: Practical guidance from a national expert panel 65
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis 65
Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: A multicenter retrospective study 64
Successful treatment with secukinumab in an HIV-positive psoriatic patient after failure of apremilast 63
Evaluation of the Impact of Night Shift Work on Disease Severity in Psoriatic Patients: A Case-Control Study with Clinical, Hormonal, and Immunological Evaluation 63
The risk of covid-19 pandemic in patients with moderate to severe plaque psoriasis receiving systemic treatments 63
Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study 63
Successful use of anti‐IL‐23 molecules in overweight‐to‐obese psoriatic patients: a multicentric retrospective study 62
Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study 62
Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience 62
Factors related to the onset and recurrence of flares in hidradenitis suppurativa patients treated with adalimumab 62
Mapping exercise and status update of eight established registries within the TREatment of ATopic eczema (TREAT) Registry Taskforce 61
The role of insomnia in the vulnerability to depressive and anxiety symptoms in atopic dermatitis adult patients 61
Alexithymia affects patients with hidradenitis suppurativa 61
Evaluation of Upadacitinib efficacy in the treatment of Atopic Dermatitis of sensitive areas 60
Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study 60
Drug survival of methotrexate and predictor factors for discontinuation in psoriasis 60
Gianotti-Crosti Syndrome after SARS-CoV-2 infection 59
Optimizing acitretin use in patients with plaque psoriasis 59
The psychological burden during COVID-19 pandemic in a cohort of patients affected by moderate-to-severe atopic dermatitis treated with dupilumab 58
Immunologic biomarkers for clinical and therapeutic management of psoriasis 58
Dusky red swelling of the penis in association with fever and diarrhoea: a quiz. Metastatic Crohn's disease of the penis associated with enteric Crohn's disease 58
Efficacy and safety of infliximab in psoriatic patients over the age of 65 57
Authors’ reply to Borg and Thoning: “Comment on: Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study” 57
Effectiveness of Secukinumab in the treatment of moderate–severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting 57
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy 57
Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort study 56
Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris 56
Testing biologics and intracellular signaling inhibitors on pediatric atopic dermatitis: a stairway to modern therapeutic approaches 56
Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian study 56
Spotlight on dupilumab in the treatment of atopic dermatitis: Design, development, and potential place in therapy 55
Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study 55
Totale 7.799
Salva come PNG Salva come JPEG
Categoria #
all - tutte 74.336
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 74.336
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202178 0 0 0 0 0 6 5 23 11 12 20 1
2021/2022466 47 2 13 11 17 4 8 45 20 96 91 112
2022/20231.894 152 189 143 311 100 235 150 176 233 61 103 41
2023/20241.859 45 374 116 272 85 252 121 90 39 93 147 225
2024/20252.959 60 40 286 66 283 129 92 93 492 251 597 570
2025/20264.324 1.291 202 591 941 1.042 257 0 0 0 0 0 0
Totale 11.733